BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16756603)

  • 1. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.
    Stanworth SJ; Dyer C; Casbard A; Murphy MF
    Vox Sang; 2006 Jul; 91(1):63-9. PubMed ID: 16756603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
    Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
    Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial.
    Estcourt LJ; McQuilten Z; Powter G; Dyer C; Curnow E; Wood EM; Stanworth SJ;
    Trials; 2019 Oct; 20(1):592. PubMed ID: 31615553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple electrode aggregometry and thromboelastography in thrombocytopenic patients with haematological malignancies.
    Opheim EN; Apelseth TO; Stanworth SJ; Eide GE; Hervig T
    Blood Transfus; 2019 May; 17(3):181-190. PubMed ID: 30747706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study.
    Estcourt LJ; Stanworth SJ; Harrison P; Powter G; McClure M; Murphy MF; Mumford AD
    Br J Haematol; 2014 Aug; 166(4):581-91. PubMed ID: 24797282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting.
    Ypma PF; Kerkhoffs JL; van Hilten JA; Middelburg RA; Coccoris M; Zwaginga JJ; Beckers EM; Fijnheer R; van der Meer PF; Brand A
    Transfus Med; 2012 Dec; 22(6):426-31. PubMed ID: 23036067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
    Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
    N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
    Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
    Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
    N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboelastography may predict risk of grade 2 bleeding in thrombocytopenic patients.
    Opheim EN; Apelseth TO; Stanworth SJ; Eide GE; Hervig T
    Vox Sang; 2017 Aug; 112(6):578-585. PubMed ID: 28639693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
    Wardrop D; Estcourt LJ; Brunskill SJ; Doree C; Trivella M; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Jul; (7):CD009733. PubMed ID: 23897323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
    Stanworth SJ; Hyde C; Brunskill S; Murphy MF
    Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy.
    Callow CR; Swindell R; Randall W; Chopra R
    Br J Haematol; 2002 Aug; 118(2):677-82. PubMed ID: 12139764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.
    Stanworth SJ; Hudson CL; Estcourt LJ; Johnson RJ; Wood EM;
    Haematologica; 2015 Jun; 100(6):740-7. PubMed ID: 25795717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal blood loss: A quantitative method of evaluating hemostasis in patients with thrombocytopenia.
    Slichter SJ; Gernsheimer T; LeBlanc R; Townsend-McCall D; Jones MK; Cuaron L; Bolgiano D
    Transfusion; 2021 Feb; 61(2):393-403. PubMed ID: 33166412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy.
    Balitsky AK; Liu Y; Van der Meer PF; Heddle NM; Arnold DM
    Transfusion; 2021 Jan; 61(1):286-293. PubMed ID: 33047878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.
    Vinholt PJ; Alnor A; Nybo M; Hvas AM
    Platelets; 2016 Sep; 27(6):547-54. PubMed ID: 27025360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.